# Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07551778/  
OnCo record `nct07551778` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cetuximab and bevacizumab (glioblastoma use) in colorectal cancer, run by BOE Technology Group Co., Ltd., not yet recruiting.

## Summary

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07551778 by BOE Technology Group Co., Ltd., with a registry enrolment figure of 42 participants, started 2026-08 and due to reach its primary completion in 2028-04. Interventions recorded: NK Cells; NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy; NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy; NK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapy; NK cells + PD-(L)1 inhibitor + capecitabine or S-1 as first-line maintenance therapy. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer; Advanced Solid Tumors; Advanced Hepatocellular Carcinoma (HCC); GC/GEJC. Primary outcome: Dose-Limiting Toxicity (DLT); Adverse Events (AE). Colorectal eligibility wording from the registry: "* Histologically/cytologically confirmed locally advanced unresectable or metastatic (unresectable Stage III or Stage IV per AJCC 8th Edition) colorectal adenocarcinoma;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07551778
- Phase: 1/2
- Setting: An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Allogeneic NK Cell Injection Combined With Standard Maintenance Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
- Sponsor: BOE Technology Group Co., Ltd.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07551778: https://clinicaltrials.gov/study/NCT07551778

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07551778.json